ArticleJACC. Case reports2026
Cardiac Arrest From Sulfur Hexafluoride Contrast Anaphylaxis After Prior Perflutren Hypersensitivity.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contrast Media Side Effects and Kounis Syndrome: Timeo Danaos et Dona Ferentes.Balkan medical journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUltrasound-enhancing agents (UEAs) are generally considered safe, with severe reactions exceptionally rare. Cross-reactivity between agents remains poorly understood. CASE SUMMARY: A 62-year old man with prior hypersensitivity to perflutren lipid microspheres contrast agent developed anaphylaxis with pulseless electrical activity arrest immediately after administration of sulfur hexafluoride lipid microspheres contrast agent. After resuscitation, return of spontaneous circulation occurred within 2 minutes. An elevated tryptase level confirmed mast cell activation. DISCUSSION: Current guidelines support the use of sulfur hexafluoride lipid microspheres in patients with hypersensitivity to perflutren lipid microspheres given an absence of established cross-reactivity between contrast agents. This case underscores the potential for life-threatening anaphylactic reactions to UEAs, even in patients with prior documented tolerance to related formulations. TAKE-HOME MESSAGES: This is to our knowledge the first reported case of sulfur hexafluoride lipid microspheres anaphylaxis resulting in cardiac arrest in a patient with prior hypersensitivity to perflutren lipid microspheres. Clinicians should anticipate cross-sensitization between UEAs and maintain immediate access to resuscitation measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.